Luminex Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/22/2026)
| Balance Sheet | Total Assets | 825,463,000.00 | ROE | – |
| Balance Sheet | Total Equity | 517,711,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -17,910,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 32,021,000.00 | – | – |
| Cashflow | Operating Cash Flow | 49,931,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 0.33 | Div. Yield | – |
| Income | Net Income | 15,170,000.00 | P/E | – |
| Income | Shares Outstanding | 45,682,687.00 | P/B | – |
| Income | Total Revenue | 417,396,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Luminex Corporation (Luminex)develops, manufactures and sells biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company´s Multi-Analyte Profiling (xMAP) technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, digital signal processors and software. Its xMAP technology is being used within various segments of the life sciences industry, which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research. On June 27, 2011, the Company completed its acquisition of 100% interest of EraGen Biosciences, Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.luminexcorp.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more